Immune responses induced by two dose strengths of an yeast-derived recombinant hepatitis B vaccine in adolescents [2] (multiple letters)

Indian Journal of Gastroenterology

Volumn 22, Issue 2, 2003, Pages 71-72

  Kakrani, A L ^a   Bharadwaj, Renu ^a   Karmarkar, Alka ^a   Joshi, Suvarna ^a   Yadav, Sachin ^a   Bhardwaj, Subodh ^b   Kulkarni, Alka ^b   Kulkarni, Sadanand ^b  

^a B J MEDICAL COLLEGE   (India)

^b Serum Institute of India Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GENEVAC B; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ADOLESCENT; ANTIBODY TITER; FEMALE; GENETIC ENGINEERING; HANSENULA POLYMORPHA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LETTER; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SEROCONVERSION; VACCINATION; VIRUS HEPATITIS; YEAST;

ADOLESCENT; ADULT; CHILD; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE;

EID: 0345701509     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Hammond GW, Parker J, Mimms L, Tate R, Sekla L, Minuk G. Comparison of immunogenicity of two yeast derived recombinant hepatitis B vaccines. Vaccine 1991;9:97-100.
2. Chiramonte M, Majori S, Ngatchu T, Moschen ME, Baldo V, Renzulli G, et al. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine 1996;14:135-7.
3. Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988;6:2301-7.